$1.620
+0.020 (+1.25%)Al cierre
Noticias de CANF
Eventos de CANF
Can-Fite BioPharma Patient Achieves Ten Years Cancer-Free Survival
Can-Fite BioPharma announced that a patient with advanced liver cancer who participated in its completed Phase II study of Namodenoson has reached ten years of overall survival and remains cancer-free and in good health. The patient's complete response was previously reported by the company. Namodenoson is currently being evaluated in Can-Fite's ongoing pivotal Phase III study in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B7 cirrhosis.
Can-Fite BioPharma Evaluates Interim Analysis Timing for Namodenoson Study
Can-Fite BioPharma announced that blinded overall survival observed across the entire patient population in its ongoing pivotal Phase III study of Namodenoson in advanced hepatocellular carcinoma, or HCC, appears longer than originally anticipated based on the assumptions underlying the study design. The pivotal Phase III study is a randomized, double-blind, placebo-controlled study evaluating Namodenoson in patients with advanced HCC and underlying Child-Pugh B7 cirrhosis. Patients are randomized 2:1 to receive Namodenoson or placebo, with overall survival as the primary efficacy endpoint. The observed survival reflects the pooled, blinded study population and includes patients receiving both Namodenoson and placebo. Accordingly, no conclusions regarding treatment efficacy or differences between the study arms can be drawn from these data at this stage. In view of the longer-than-anticipated survival observed in the study population, Can-Fite is evaluating an earlier timing for the study's planned interim analysis. The interim analysis will enable an independent assessment of overall survival between the Namodenoson and placebo treatment groups in accordance with the study's statistical analysis plan and applicable regulatory requirements.
Can-Fite BioPharma Files $100M Mixed Securities Shelf
Can-Fite BioPharma files $100M mixed securities shelf
Can-Fite BioPharma Submits Piclidenoson Clinical Study Protocol
Can-Fite BioPharma announced the submission of a Phase 2 clinical study protocol to Bambino Gesu Children's Hospital in Rome, Italy, for the first clinical evaluation of Piclidenoson in patients with Lowe syndrome, a rare inherited genetic disorder with no approved disease-modifying therapies. The study will be led by Francesco Emma, an internationally recognized expert in inherited kidney diseases.
Can-Fite Secures Australian Patent for Advanced Cancer Treatment
Can-Fite BioPharma announced that the Australian Patent Office has allowed Patent Application No. 2021290439 entitled "Treatment of Advanced Metastatic Cancer." The patent complements Can-Fite's oncology pipeline. Namodenoson is currently being evaluated in a pivotal Phase 3 study for advanced hepatocellular carcinoma following FDA and EMA protocol agreement. In pancreatic cancer, the company recently completed a Phase 2a clinical study demonstrating an excellent safety profile together with encouraging survival outcomes and durable disease stabilization and is planning a Phase 2b study evaluating Namodenoson in combination with gemcitabine.
Artículos relacionados
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.